Podcasts about Staphylococcus

Story at-a-glance Your scalp hosts a dense microbial ecosystem that protects against inflammation and disease. When disrupted, it can lead to flaking, itching, thinning hair, and inflammatory scalp conditions like seborrheic dermatitis The scalp microbiome is dominated by key bacteria like Cutibacterium acnes and Staphylococcus epidermidis. These microbes help protect your skin barrier, manage inflammation, and regulate other harmful organisms Scalp dysbiosis can be triggered by overwashing, harsh shampoos, excessive oil production, and even genetic factors like hair density or dandruff-prone skin. These disrupt the balance of good and bad microbes Dandruff is linked to reduced microbial diversity and fungal overgrowth. Studies show healthy scalps have more protective bacteria, while dandruff-prone scalps are overrun with inflammatory microbes like Malassezia restricta and Malassezia globosa Long-term relief comes from restoring beneficial microbes, not just killing fungi. Using microbiome-safe natural products, avoiding daily shampooing, and consuming foods that promote the growth of probiotics, prebiotics, and postbiotics are effective ways to rebalance your scalp naturally

This podcast is based upon the new 'Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID)' available HERE   (00:00) John introduces the podcast with his co-hosts Sue Paterson & Producer Paul.   Chapter 1 – Understanding Pyoderma and the Need for New Guidelines   (02:56) Sue welcomes Dr. Anette Loeffler, who introduces herself and her background in veterinary dermatology. Originally from Germany, she studied in Munich and has worked in the UK for over 30 years. She is currently a dermatologist at the Royal Veterinary College (RVC) and has a special interest in Staphylococcus and bacterial skin infections and this has led her to work over the last 4 years on the new pyoderma treatment guidelines, aimed at improving antibiotic use and promoting topical therapy.   (04:30) Sue asks Anette to explain antimicrobial stewardship and why it is important. Anette describes antimicrobial resistance as a major global threat. Overuse of antibiotics leads to resistance, so it is crucial to avoid unnecessary prescriptions and focus on appropriate diagnostics.   (06:10) Sue asks how common pyoderma is in domestic species, particularly dogs and cats. Anette explains that staphylococcal pyoderma is very common in dogs due to their unique skin structure, making them more prone to bacterial overgrowth. While cats and other species can develop bacterial skin infections, it is far less frequent and usually not recurrent.   Chapter 2 – Diagnosing and Classifying Pyoderma   (08:00) John discusses evolving perspectives on pyoderma classification and asks if the traditional categories of superficial and deep pyoderma are still relevant. Anette confirms that the new guidelines still use these classifications as they help determine treatment:   Surface pyoderma (dysbiosis): Often in skin folds where bacteria and yeast overgrow due to friction and moisture. Superficial pyoderma: Involves hair follicles and is the most common type. Deep pyoderma: A more serious infection requiring systemic antibiotics.   (10:19) Sue notes that past treatment approaches lacked strong clinical evidence. Anette explains that many historical treatment protocols were based on anecdotal evidence rather than research. While deep pyoderma has more robust studies, superficial cases often lacked proper research, leading to overuse of antibiotics.   (13:04) John asks how vets can determine whether a case is surface, superficial, or deep pyoderma. Anette explains that clinical examination alone can often differentiate them:   Surface infections show redness and are in friction areas (e.g., nasal folds, hotspots). Superficial pyoderma presents with papules, pustules, and epidermal collarettes. Deep pyoderma causes swelling, draining tracts, haemorrhagic crusting, and pain.   (16:04) Sue asks how to confirm true bacterial pyoderma and rule out mimicking conditions. Anette stresses the importance of cytology, a simple and cost-effective test that can quickly confirm bacterial involvement. Cytology can also differentiate between bacterial infections, yeast overgrowth, and sterile pustular diseases.     Chapter 3 – Treatment Approaches and Key Takeaways from the New Guidelines   (19:36) John asks about traditional treatment approaches and why they need updating. Anette outlines how older guidelines recommended unnecessarily long courses of antibiotics (e.g., 3-4 weeks for superficial pyoderma, 4-6 weeks for deep pyoderma). While this was logical before antimicrobial resistance became a concern, modern research supports shorter, targeted treatments. (26:13) Anette explains the new recommendations:   Surface pyoderma should be treated topically only – systemic antibiotics are inappropriate. Superficial pyoderma should primarily be treated with topical therapy – which has been shown to be as successful as a course of antibiotics. Deep pyoderma requires systemic antibiotics but can benefit from adjunctive topical treatment.   (32:40) Sue asks about helping vets communicate these new approaches to pet owners. Anette explains that the guidelines include tables, visual aids, and quick-reference guides to support busy practitioners.   (33:28) John asks about when systemic antibiotics are still necessary. Anette explains that systemic therapy is still essential for deep pyoderma or when topical treatment alone is impractical (e.g., large dogs, owner limitations). In such cases, culture and susceptibility testing should guide antibiotic choice.   (38:15) Sue asks which antibiotics should be the first choice if empirical treatment is necessary. Anette recommends clindamycin, lincomycin, cephalexin, or co-amoxiclav as first-line choices, with fluoroquinolones reserved for resistant infections.   (42:32) Sue asks Anette for her top five takeaways from the guidelines:   Read the dog, not just the textbook. Diagnose based on clinical lesions and determine if the infection is surface, superficial, or deep.   Use cytology whenever possible. It's quick, inexpensive, and helps confirm bacterial involvement.   Always look for the underlying cause. Pyoderma often recurs due to allergies or hormonal conditions.   Prioritise topical therapy. Topical antimicrobials alone are effective for many skin infections, reducing antibiotic use.   Use systemic antibiotics responsibly. Empirical choices should be limited to first-line drugs, and culture should guide second-line therapy.   (45:45) Sue mentions that the full guidelines will be available online via: WSAVA, ISCAID, and WAVD. Sue also mentioned a  WAVD webinar Anetta hosted, which is a must watch. The guidelines are currently available HERE   (47:29) Outro – As always, Sue & John wrap up before John asks his co-hosts a light-hearted question to end on

This episode of Communicable takes on a special format where editors of CMI Comms, Marc Bonten, Josh Davis, Erin McCreary, Emily McDonald, all clinical trialists in their own right, take turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna. These include the CloCeBa trial on Staphylococcus aureus bacteraemia treatment options, the Taper V trial on vancomycin as prophylaxis for Clostridioides difficile infection, the ASTARTÉ trial on temocillin versus meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales, the HARVEST trial investigating high doses of rifampicin for tuberculosis meningitis, and the CAP5 trial on shortening antibiotic treatment for community-acquired pneumonia.   This episode was peer reviewed by Dr. Barbora Píšová (Czech Republic) and is the first of a two-part series covering selected clinical trials presented at ESCMID Global 2025. References: Lescure X, et al. Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trialMcDonald EG, et al. Initial vancomycin taper for the prevention of recurrent Clostridioides difficile infection: the TAPER-V randomised controlled trialCogliati Dezza F, et al. Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trialVan Crevel R, et al. High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trialBastrup Israelsen S, et al. Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial

Send us a textEpisódio 54 – Hipotermia, Crescimento, Infecção Metabólica e Nariz Eletrônico na NeonatologiaNeste episódio especial, apresentamos os destaques do Encontro Internacional de Neonatologia, realizado nos dias 4 e 5 de abril em Gramado, sob a mais uma vez brilhante organização dos professores Rita e Renato Procianoy. Um evento que reuniu especialistas do Brasil e do mundo para discutir os avanços mais recentes no cuidado neonatal — e nós não poderíamos deixar de compartilhar com vocês, ouvintes que acompanham quinzenalmente o nosso Journal Club em língua portuguesa.Selecionamos quatro estudos que marcaram as discussões científicas durante o encontro:1. Whole-Body Hypothermia vs Targeted Normothermia for Neonates With Mild Encephalopathy – Este ensaio clínico multicêntrico coloca em pauta uma pergunta que muitos de nós enfrentamos à beira do leito: recém-nascidos com encefalopatia leve devem ser resfriados?2. Glucose supply and glycolysis inhibition shape the clinical fate of Staphylococcus epidermidis-infected preterm newborns – Uma fascinante investigação experimental que conecta metabolismo energético e resposta inflamatória em prematuros infectados, com possíveis implicações clínicas na prevenção da disfunção orgânica.3.Monitoring the Postnatal Growth of Preterm Infants: A Paradigm Change – Este artigo propõe uma verdadeira mudança de paradigma na forma como monitoramos o crescimento de prematuros, destacando a importância de uma abordagem individualizada e centrada no bebê. 4. Longitudinal fecal microbiota and volatile metabolomics preceding necrotizing enterocolitis in preterm infants– Um estudo que combina análise do microbioma e metabolômica para identificar marcadores precoces de enterocolite necrosante, uma das doenças mais temidas da neonatologia.Esperamos que este episódio especial amplie seu repertório científico e inspire práticas ainda mais seguras e baseadas em evidências. Se você gosta do nosso conteúdo, avalie o programa na sua plataforma de streaming e compartilhe com colegas e interessados. Seu apoio é essencial para continuarmos promovendo a neonatologia em língua portuguesa!Até o próximo episódio! Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

In dieser Folge geht es um Neuigkeiten in der Therapie bei Stphylococcus aureus Bakteriämie. Till war auf dem ESCMID global 2025 in Wien und dort wurden Ergebnisse aus den Studien CloCeBa und dem großen SNAP-Trail vorgestellt. Die Ergebnisse sind „practice changing“ und werden unser klinisches Management der Staph. aureus Blutstrominfektion verändern. Viel Spaß beim Hören! … „#94: News zur Staphylococcus aureus Blutstrominfektion: CloCeBa und SNAP“ weiterlesen

Breakpoints joins forces with CMI Communications' Communicable podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025. Hosts Drs. Erin McCreary and Angela Huttner interview SNAP trial investigators, Drs. Joshua Davis and Steven Tong, on results from penicillin-susceptible and methicillin-susceptible Staphylococcus aureus domains. Conflict of Interest for DSMC Members: Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationship that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner. Each DSMC candidate was well vetted.

In this first-ever collaboration between Communicable and Breakpoints, the podcast of the US Society of Infectious Diseases Pharmacists, hosts Angela Huttner (Geneva, Switzerland) and Erin McCreary (Pittsburgh, USA) join trial investigators Josh Davis (Newcastle, Australia) and Steve Tong (Melbourne, Australia) to unpack the first results coming from the SNAP adaptive platform trial, which were recently presented at ESCMID Global in Vienna. Learn whether penicillin and cefazolin are non-inferior to—and maybe even safer than—flucloxacillin for penicillin-susceptible and methicillin-susceptible Staphylococcus aureus, respectively.This episode was edited by Julie Anne Justo, transcribed by Katie Lambert and Sarah Groom, and peer-reviewed by Megan Klatt and Lacy Worden. Note on conflict of interest for SNAP Data Safety Monitoring Committee (DSMC) members:Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationships that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner. Literature:Steven Y. C. Tong, Joshua S. Davis, Emily Eichenberger et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015 Jul;28(3):603-61.SNAP Adaptive trial platform/results of the PSSA & MSSA domains: https://www.snaptrial.com.au/ESCMID Global April 2025 presentation:www.online.escmid.org *https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/CloCeBa trial results (ESCMID Global April 2025 presentation): www.online.escmid.org *https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/Note on access to online video of ESCMID Global presentations:In the six months following the congress:Non-ESCMID members have access if they registered for ESCMID GlobalMembers have access only if they registered for ESCMID GlobalSix months after the congress:Non-members do not have access, whatever their ESCMID Global registration statusAll members have access, whatever their ESCMID Global registration statusCAMERA 2 trial: Steven Y. C. Tong, David C. Lye, Dafna Yahav, et al. Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA BacteremiaA Randomized Clinical Trial. JAMA. 2020;323(6):527-537. doi:10.1001/jama.2020.0103 POET trial: Kasper Iversen, Nikolaj Ihlemann, Sabine U. Gill et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019;380:415-424POET trial follow-up: Mia M. Pries-Heje, Christoffer Wiingaard, Nikolaj Ihlemann. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial. N Engl J Med 2022;386:601-602

What exciting times! Clinical trials into the management of SAB! SNAP publication on the horizon! But how do we interpret and apply the results of these trials to our patients? This week Jame and Callum are joined by Dr Clark Russell, Clinical Lecturer in Infectious Diseases to discuss:The difficulty in interpreting current clinical trials in SAB.The emerging concept of "low risk" SAB and how to define this.The heterogeneity of SAB and how this might be exploited.Notes for this episode here: https://idiots.notion.site/107-SAB-update-1316a1ea09d8800ba701ca7ebc8d4093 Previous episodes for the basics of Staphylococcus aureus and SABATO & SNAP trials:1. It starts with Staph65. SNAP trial protocol72. SABATO trial & 73. SABATaddendumSend us a text Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

Do you keep relapsing after treating candida, SIBO or other conditions? The culprit behind these never-ending cycles may be biofilms. In this episode, I'll explain how biofilms form, help you identify signs that you have them, and recommend the best antibiofilm agents. Tune in!   Learn more about biofilms and improve your gut now! Reach out to our virtual clinic: https://drruscio.com/virtual-clinic/  

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the USF Morsani College of Medicine, Division of Infectious Diseases, presents a case-based discussion of gram positive organisms producing disease in humans. Infections discussed include Staphylococcus aureus, Coagulase negative Staphylococcus, Pneumococcus, Streptococcus spp., Enterococcus, Corynebacterium, Bacillus, and Erysipelothrix. Associated clinical syndromes are also discussed.

We've all felt the instant relief of scratching an itch, but what if that fleeting moment of bliss was actually doing more than just satisfying an itch? Scientists have just published new research in the journal Science which shows how scratching activates an immune response that can help protect the skin against harmful infections. Scratching has long been thought to serve a practical function: removing irritants like insects, dust, or allergens. But some itches, such as those caused by mosquito bites, persist long after the culprit is gone. This suggests that scratching might serve another purpose beyond simply removing irritants. Researchers induced an itchy allergic contact dermatitis on the ears of mice have of which were allowed to scratch the itch and half that couldn't due to wearing a tiny headcollar. The mice that were allowed to scratch developed increased swelling and a surge of immune cells called neutrophils at the site. However, the mice that were prevented from scratching, had significantly lower inflammation and fewer immune cells in the affected area. The researchers found that scratching activates pain-sensing neurons, which then release a powerful neurochemical called substance P. This messenger molecule wakes up mast cells which are immune cells that play a key role in allergic reactions. Once activated, mast cells recruit neutrophils, amplifying inflammation at the scratched site. Previously, scientists believed that mast cells were only triggered by allergens, however this study revealed an entirely new pathway: scratching itself can activate these immune responses. While this might sound like a bad thing, it turns out that it has a hidden benefit. The team discovered that scratching isn't just about relief, it also helps to keep dangerous bacteria at bay. In their experiment, they found that mice who were allowed to scratch had lower levels of the potentially harmful bacteria Staphylococcus aureus on their skin compared to those prevented from scratching. This suggests that scratching might have antibacterial effects, helping to remove harmful microbes before they cause infection. Of course, not all scratching is beneficial. Chronic scratching, as seen in conditions like eczema or diabetes, can lead to skin damage and increase the risk of infection. In these cases, the same immune response that helps in the short term can become a problem if it's constantly activated. Interestingly, researchers identified two separate nerve pathways, one that signals an itch and another that controls the immune response from scratching. This discovery opens the door to potential treatments that could block the itch-scratch cycle while preserving the immune benefits of scratching. Scientists hope that by targeting specific nerve pathways, they can develop new therapies that stop the discomfort without shutting down the body's natural immune defences. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Dr. Don - not risky

We are pleased to announce the first of a new series of upcoming episodes, titled ‘Pulse Check – Key Papers at a Glance'. Our host Can discuss two recent and impactful EJCTS articles on infective endocarditis. Joined by the renowned, Michael Borger and Torsten Doenst, we explore firstly the implications of preoperative septic cerebral embolism for patients undergoing valve surgery. Then followed by an exploration into the use of haemoadsorption therapy, addressing the key issue of controlling inflammation during cardiac surgery for endocarditis. Listen to gain rapid insight into the associated articles: Effect of haemoadsorption during cardiac surgery for Staphylococcus aureus endocarditis: a REMOVE trial post hoc analysis Outcomes following heart valve surgery in patients with infective endocarditis and preoperative septic cerebral embolism: insights from the CAMPAIGN study group'

Man Says He Visited Heaven, Met Jesus During Near-Death Experience Watch this video at- https://youtu.be/3FQmcCFZ8Ng?si=x4U0Eezqh21CuDDg CBN News 2.28M subscribers 123,685 views May 16, 2024 Randy Kay's "afterlife" experience still leaves him visibly emotional as he recounts details of visiting heaven, meeting Jesus, and returning to share his harrowing journey. Kay, author of the book, "Heaven Stormed: A Heavenly Encounter Reveals Your Assignment in the End Time Outpouring and Tribulation," told CBN News he was once a denier of near-death experience claims — until he faced his own purported heaven journey. He recalled his own afterlife experience, which began with a sore calf. At first, he thought he had strained a muscle, but while working out and going on a bike ride, his calf began to swell. "I was able to make it back home and then went to the doctor to get an anti-inflammatory prescription, and lo and behold, when I pressed my heel into the floor as the doctor had suggested, I collapsed," Kay said. "And I was rushed to the emergency room." It turns out, the pain and swelling were due to seven blood clots that had formed. He then contracted Methicillin-resistant Staphylococcus aureus (MRSA), a drug-resistant bacteria. "The doctor said I was a walking dead man," Kay said. "And then the septic shock which entered into my body caused a traffic jam in my vessels, my vascular system." The chaos landed Kay in a dire situation — one that he believes sent him to heaven. "Everything went dark initially and the next moment of recall, I was looking down on my body," he said. "I was being pulled by this light. I know that sounds cliche, almost, but it's absolutely true." Kay continued, "I was in a kind of very vague, ethereal space initially where I saw these figures in front of me, and they were warring against each other. There's no other way of putting it." After his return from his after-death experience, Kay discerned he was watching spiritual warfare play out. Regardless of what people choose to believe, Kay's physical body was dead at this point, making these memories and claims quite fascinating. "My heart had stopped," he said, noting that hospital records indicate he was clinically dead for 30 minutes and 49 seconds. During that time, Kay believes he was experiencing heaven, noting he was aware that her was himself but suddenly was seeing and visualizing the world quite differently. "I was seeing things, hearing things beyond which I would be able to do otherwise in my body," he said.

In this episode of Skin Anarchy, host Dr. Ekta welcomes Dr. Barbara Paldus, founder of Codex Labs, to explore breakthrough insights into eczema treatment. Dr. Paldus delves into the science behind the skin-gut-brain microbiome axis and explains how addressing both internal and external factors can revolutionize eczema care. Drawing on her recent TED Talk, she reveals that supporting gut health, reducing systemic inflammation, and restoring a balanced skin barrier can yield up to three times the benefits of traditional topical treatments.Dr. Paldus outlines the two main theories behind eczema—whether it starts with a leaky gut or a weakened skin barrier—and emphasizes that true relief comes from a holistic approach. She shares compelling data and real-world results from Codex Labs' innovative products, including the Bia Unscented Soap, Bia Eczema Relief Lotion, and Antü Skin Barrier Support Supplement. These products are designed to soothe, hydrate, and strengthen the skin from within, proving effective even in rigorous clinical trials.The conversation highlights the importance of understanding the genetic and environmental factors that contribute to eczema, from mutations in the filaggrin gene to the role of Staphylococcus aureus. Dr. Paldus also offers practical advice on integrating dietary changes, stress management, and gentle skincare into a comprehensive routine that supports long-term skin health.Tune in to discover how combining cutting-edge science with holistic wellness is paving the way for a new era in eczema treatment and learn why taking care of your skin from the inside out is the future of dermatology.Shop Codex's NEW Bia Eczema Relief Lotion.To learn more about Codex Labs, visit their website and social media. Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Arctic air is on the move southward and eastward into the United States in the coming days and will create harsh conditions for millions prior to the end of February. Also, the "superbug bacteria" is the methicillin-resistant Staphylococcus aureus, which resists most antibiotics, causes lung scarring and could cause death. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Drs. Henry “Chip” Chambers and Warren Rose join Dr. Megan Klatt to tackle rifampin dosing for gram-positive infections. In this episode, they break down rifampin synergy studies and discuss what is the optimal dosing of rifampin for challenging gram-positive bacterial cases, in particular Staphylococcus aureus infections with or without retained hardware/devices.   Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis. Open Forum Infect Dis. 2022 Oct 31;9(11):ofac583. doi: 10.1093/ofid/ofac583. PMID: 36408468. Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2023 Oct 3;78(10):2419-2427. doi: 10.1093/jac/dkad214. PMID: 37583062. Adjunctive Rifampin Following Debridement and Implant Retention for Staphylococcal Prosthetic Joint Infection: Is it Effective if not Combined With a Fluoroquinolone? Open Forum Infect Dis. 2022 Oct 31;9(12):ofac582. doi: 10.1093/ofid/ofac582. PMID: 36504699.

Drs. Nico Cortes-Penfield (@Cortes-Penfield), Kerry LaPlante (@Kerry_LaPlante), Jessica Seidelman (@JessieLSeidel) join Dr. Julie Ann Justo (@julie_justo) to discuss the pesky slime that is biofilm in periprosthetic joint infections. They review biofilm composition & development, have an honest discussion about whether antibiotics can ever really eradicate it, and provide updates on the promising non-pharmacologic strategies on the horizon (bacteriophages, electromagnetism, & more). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections. Breakpoints Podcast Episode #67. Society of Infectious Diseases Pharmacists. Dosing Consult: Rifampin Part 1. Breakpoints Podcast Episode #104. Society of Infectious Diseases Pharmacists. Review on Staphylococcal biofilm development: Schilcher K, Horswill AR. 2020 Aug 12;84(3):e00026-19. doi: 10.1128/MMBR.00026-19. PMID: 32792334. Antibiotics can fail to kill biofilm cells even if they penetrate the biofilm: Singh R, et al. Pathog Dis. 2016 Aug;74(6):ftw056. doi: 10.1093/femspd/ftw056. Epub 2016 Jul 7. PMID: 27402781. Subinhibitory antibiotic concentrations can promote biofilm formation: Schilcher K, et al. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5957-67. doi: 10.1128/AAC.00463-16. PMID: 27458233. Clinical and genetic risk factors for biofilm-forming Staphylococcus aureus: Luther MK, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02252-17. doi: 10.1128/AAC.02252-17. PMID: 29530854. Meta-analysis showing poor clinical outcomes with debridement, antibiotics, and implant retention (DAIR): Kunutsor SK, et al. J Infect. 2018 Dec;77(6):479-488. doi: 10.1016/j.jinf.2018.08.017. PMID: 30205122. Thieme L, et al. MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. Biol Proced Online 21, 18 (2019). https://doi.org/10.1186/s12575-019-0106-0. Ongoing trial investigating use of MBEC in the treatment of PJIs: Tillander JAN, et al. BMJ Open. 2022 Sep 15;12(9):e058168. doi: 10.1136/bmjopen-2021-058168. PMID: 36109038. Maale, G. Complete eradication of biofilm using low frequency electromagnetic force (EMF) and antibiotics at MIC. 34th Annual Meeting Musculoskeletal Infection Society. 2024 Aug. Abstract 1232 (see full program). Meta-analysis on bacteriophages for biofilm: Kovacs CJ, et al. Mil Med. 2024 May 18;189(5-6):e1294-e1302. doi: 10.1093/milmed/usad385. PMID: 37847552. Berking BB, et al. Biofilm disruption from within: light-activated molecular drill-functionalized polymersomes bridge the gap between membrane damage and quorum sensing-mediated cell death. ACS Biomater Sci Eng. 2024 Sep 9;10(9):5881-5891. doi: 10.1021/acsbiomaterials.4c01177. PMID: 39176452. Aboelnaga N, et al. Deciphering the dynamics of methicillin-resistant Staphylococcus aureus biofilm formation: from molecular signaling to nanotherapeutic advances. Cell Commun Signal. 2024 Mar 22;22(1):188. doi: 10.1186/s12964-024-01511-2. PMID: 38519959. Conway J, et al. Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0065524. doi: 10.1128/aac.00655-24. PMID: 39012102. Mulpur P, et al. Efficacy of intrawound vancomycin in prevention of periprosthetic joint infection after primary total knee arthroplasty: a prospective double-blinded randomized control trial. J Arthroplasty. 2024 Jun;39(6):1569-1576. doi: 10.1016/j.arth.2024.01.003. PMID: 38749600. Dong Y, et al. Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm. J Antimicrob Chemother. 2013 Apr;68(4):816-26. doi: 10.1093/jac/dks490. PMID: 23248238. Miltenberg B, et al. Intraosseous Regional Administration of Antibiotic Prophylaxis for Total Knee Arthroplasty: A Systematic Review. J Arthroplasty. 2023 Apr;38(4):769-774. doi: 10.1016/j.arth.2022.10.023. PMID: 36280158. Viswanathan VK, et al. Intraosseous regional antibiotic prophylaxis in total joint arthroplasty (TJA): Systematic review and meta-analysis. J Clin Orthop Trauma. 2024 Oct 3;57:102553. doi: 10.1016/j.jcot.2024.102553. PMID: 39435324. SOLARIO trial: Dudareva M, et al. The European Bone and Joint Infection Society Meeting, 2024 Sept. SOLARIO trial press release from BoneSupportTM. 2024 Oct 3. Fehring TK, et al. Does treatment at a specialized prosthetic joint infection center improve the rate of reimplantation. J Arthroplasty. 2023 Jun;38(6S):S314-7. PMID 37004968. ROADMAP trial website. 2024.

In this episode of the Micro Binfie Podcast, host Andrew Page takes listeners to the heart of the microbial genomics hackathon in Bethesda, Maryland, for an engaging conversation with special guest Megan Phillips, a PhD student from Emory University. Megan delves into her research on Staphylococcus aureus (MRSA), highlighting its fascinating dual nature as both a harmless and potentially serious pathogen. Megan discusses the complexities of tetracycline resistance, particularly focusing on plasmid-mediated mechanisms involving the pt181 plasmid. She explains how this plasmid's efflux pump, encoded by the gene tetK, contributes to variable resistance levels and the factors influencing MIC (Minimum Inhibitory Concentration) variability. Listeners will learn about the intricacies of plasmid copy numbers, their global spread across clonal complexes, and the occurrence of horizontal and vertical gene transfer. Throughout the episode, Megan shares insights on working with short-read sequencing data and the strategies she employs to detect plasmid presence using tools like BLAST. She also touches on the challenges and fascinating discoveries of tracking historical sample data and integrating findings from older research papers, showcasing her appreciation for the poetic style of scientific writing from the 1940s. For those interested in antimicrobial resistance, evolutionary microbiology, and the subtleties of bacterial genome analysis, this episode offers a compelling blend of technical details and engaging storytelling. Tune in to hear more about Megan's upcoming publications, her experiences navigating complex genomic data, and her thoughts on antimicrobial stewardship and historical perspectives on drug resistance.

Guest: Dr. Christian de Virgilio is the Chair of the Department of Surgery at Harbor-UCLA Medical Center. He is also Co-Chair of the College of Applied Anatomy and a Professor of Surgery at UCLA's David Geffen School of Medicine. He completed his undergraduate degree in Biology at Loyola Marymount University and earned his medical degree from UCLA. He then completed his residency in General Surgery at UCLA-Harbor Medical Center followed by a fellowship in Vascular Surgery at the Mayo Clinic.   Resources:  Rutherford Chapters (10th ed.): 174, 175, 177, 178 Prior Holding Pressure episode on AV access creation: https://www.audiblebleeding.com/vsite-hd-access/ The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access: https://www.jvascsurg.org/article/S0741-5214%2808%2901399-2/fulltext  KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update: https://pubmed.ncbi.nlm.nih.gov/32778223/    Outline: Steal Syndrome Definition & Etiology Steal syndrome is an important complication of AV access creation, since access creation diverts arterial blood flow from the hand. Steal can be caused by multiple factors—arterial occlusive disease proximal or distal to the AV anastomosis, high flow through the fistula at the expense of distal arterial perfusion, and failure of the distal arterial networks to adapt to this decreased blood flow.  Incidence and Risk Factors The frequency of steal syndrome is 1.6-9%1,2, depending on the vessels and conduit choice Steal syndrome is more common with brachial and axillary artery-based accesses and nonautogenous conduits. Other risk factors for steal syndrome are peripheral vascular disease, coronary artery disease, diabetes, advanced age, female sex, larger outflow conduit, multiple prior permanent access procedures, and prior episodes of steal.3,4  Long-standing insulin-dependent diabetes causes both medial calcinosis and peripheral neuropathy, which limits arteries' ability to vasodilate and adjust to decreased blood flow. Patient Presentation, Symptoms, Grading Steal syndrome is diagnosed clinically.  Symptoms after AVG creation occurs within the first few days, since flow in prosthetic grafts tend to reach a maximum value very early after creation. Native AVFs take time to mature and flow will slowly increase overtime, leading to more insidious onset of symptoms that can take months or years. The patient should have a unilateral complaint in the extremity with the AV access. Symptoms of steal syndrome, in order of increasing severity, include nail changes, occasional tingling, extremity coolness, numbness in fingertips and hands, muscle weakness, rest pain, sensory and motor deficits, fingertip ulcerations, and tissue loss.  There could be a weakened radial pulse or weak Doppler signal on the affected side, and these will become stronger after compression of the AV outflow. Symptoms are graded on a scale specified by Society of Vascular Surgery (SVS) reporting standards:5  Workup Duplex ultrasound can be used to analyze flow volumes. A high flow volume (in autogenous accesses greater than 800 mL/min, in nonautogenous accesses greater than 1200 mL/min) signifies an outflow issue. The vein or graft is acting as a pressure sink and stealing blood from the distal artery. A low flow volume signifies an inflow issue, meaning that there is a proximal arterial lesion preventing blood from reaching the distal artery. Upper extremity angiogram can identify proximal arterial lesions. Prevention Create the AV access as distal as possible, in order to preserve arterial inflow to the hand and reduce the anastomosis size and outflow diameter.  SVS guidelines recommend a 4-6mm arteriotomy diameter to balance the need for sufficient access flow with the risk of steal. If a graft is necessary, tapered prosthetic grafts are sometimes used in patients with steal risk factors, using the smaller end of the graft placed at the arterial anastomosis, although this has not yet been proven to reduce the incidence of steal.  Indications for Treatment Intervention is recommended in lifestyle-limiting cases of Grade II and all Grade III steal cases. If left untreated, the natural history of steal syndrome can result in chronic limb ischemia, causing gangrene with loss of digits or limbs. Treatment Options Conservative management relies on observation and monitoring, as mild cases of steal syndrome may resolve spontaneously. Inflow stenosis can be treated with endovascular intervention (angioplasty with or without stent) Ligation is the simplest surgical treatment, and it results in loss of the AV access. This is preferred in patients with repetitive failed salvage attempts, venous hypertension, and poor prognoses. Flow limiting procedures can address high volumes through the AV access. Banding can be performed with surgical cutdown and placement of polypropylene sutures or a Dacron patch around the vein or graft. The Minimally Invasive Limited Ligation Endoluminal-Assisted Revision (MILLER) technique employs a percutaneous endoluminal balloon inflated at the AVF to ensure consistency in diameter while banding Plication is when a side-biting running stitch is used to narrow lumen of the vein near the anastomosis. A downside of flow-limiting procedures is that it is often difficult to determine how much to narrow the AV access, as these procedures carry a risk of outflow thrombosis. There are also surgical treatments focused on reroute arterial inflow. The distal revascularization and interval ligation (DRIL) procedure involves creation of a new bypass connecting arterial segments proximal and distal to the AV anastomosis, with ligation of the native artery between the AV anastomosis and the distal anastomosis of the bypass. Reversed saphenous vein with a diameter greater than 3mm is the preferred conduit. Arm vein or prosthetic grafts can be used if needed, but prosthetic material carries higher risk of thrombosis. The new arterial bypass creates a low resistance pathway that increases flow to distal arterial beds, and interval arterial ligation eliminates retrograde flow through the distal artery.  The major risk of this procedure is bypass thrombosis, which results in loss of native arterial flow and hand ischemia. Other drawbacks of DRIL include procedural difficulty with smaller arterial anastomoses, sacrifice of saphenous or arm veins, and decreased fistula flow. Another possible revision surgery is revision using distal inflow (RUDI). This procedure involves ligation of the fistula at the anastomosis and use of a conduit to connect the outflow vein to a distal artery. The selected distal artery can be the proximal radial or ulnar artery, depending on the preoperative duplex. The more dominant vessel should be spared, allowing for distal arterial beds to have uninterrupted antegrade perfusion. The nondominant vessel is used as distal inflow for the AV access. RUDI increases access length and decreases access diameter, resulting in increased resistance and lower flow volume through the fistula. Unlike DRIL, RUDI preserves native arterial flow.  Thrombosis of the conduit would put the fistula at risk, rather than the native artery.  The last surgical revision procedure for steal is proximalization of arterial inflow (PAI). In this procedure, the vein is ligated distal to the original anastomosis site and flow is re-established through the fistula with a PTFE interposition graft anastomosed end-to-side with the more proximal axillary artery and end-to-end with the distal vein. Similar to RUDI, PAI increases the length and decreases the diameter of the outflow conduit. Since the axillary artery has a larger diameter than the brachial artery, there is a less significant pressure drop across the arterial anastomosis site and less steal. PAI allows for preservation of native artery's continuity and does not require vein harvest.  Difficulties with PAI arise when deciding the length of the interposition graft to balance AV flow with distal arterial flow. 2. Ischemic Monomelic Neuropathy Definition Ischemic monomelic neuropathy (IMN) is a rare but serious form of steal that involves nerve ischemia. Severe sensorimotor dysfunction is experienced immediately after AV access creation. Etiology IMN affects blood flow to the nerves, but not the skin or muscles because peripheral nerve fibers are more vulnerable to ischemia. Incidence and Risk Factors IMN is very rare; it has an estimated incidence of 0.1-0.5% of AV access creations.6 IMN has only been reported in brachial artery-based accesses, since the brachial artery is the sole arterial inflow for distal arteries feeding all forearm nerves. IMN is associated with diabetes, peripheral vascular disease, and preexisting peripheral neuropathy that is associated with either of the conditions. Patient Presentation Symptoms usually present rapidly, within minutes to hours after AV access creation. The most common presenting symptom is severe, constant, and deep burning pain of the distal forearm and hand. Patients also report impairment of all sensation, weakness, and hand paralysis. Diagnosis of IMN can be delayed due to misattribution of symptoms to anesthetic blockade, postoperative pain, preexisting neuropathy, a heavily bandaged arm precluding neurologic examination. Treatment Treatment is immediate ligation of the AV access. Delay in treatment will quickly result in permanent sensorimotor loss.   3. Perigraft Seroma Definition A perigraft seroma is a sterile fluid collection surrounding a vascular prosthesis and is enclosed within a pseudomembrane. Etiology and Incidence Possible etiologies include: transudative movement of fluid through the graft material, serous fluid collection from traumatized connective tissues (especially the from higher adipose tissue content in the upper arm), inhibition of fibroblast growth with associated failure of the tissue to incorporate the graft, graft “wetting” or kinking during initial operation, increased flow rates, decreased hematocrit causing oncotic pressure difference, or allergy to graft material. Seromas most commonly form at anastomosis sites in the early postoperative period. Overall seroma incidence rates after AV graft placement range from 1.7–4% and are more common in grafts placed in the upper arm (compared to the forearm) and Dacron grafts (compared to PTFE grafts).7-9 Patient Presentation and Workup Physical exam can show a subcutaneous raised palpable fluid mass Seromas can be seen with ultrasound, but it is difficult to differentiate between the types of fluid around the graft (seroma vs. hematoma vs. abscess) Indications for Treatment Seromas can lead to wound dehiscence, pressure necrosis and erosion through skin, and loss of available puncture area for hemodialysis Persistent seromas can also serve as a nidus for infection. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines10 recommend a tailored approach to seroma management, with more aggressive surgical interventions being necessary for persistent, infected-appearing, or late-developing seromas.   Treatment The majority of early postoperative seromas are self-limited and tend to resolve on their own Persistent seromas have been treated using a variety of  methods-- incision and evacuation of seroma, complete excision and replacement of the entire graft, and primary bypass of the involved graft segment only. Graft replacement with new material and rerouting through a different tissue plane has a higher reported cure rate and lower rate of infection than aspiration alone.9     4. Infection Incidence and Etiology The reported incidence of infection ranges 4-20% in AVG, which is significantly higher than the rate of infection of 0.56-5% in AVF.11  Infection can occur at the time of access creation (earliest presentation), after cannulation for dialysis (later infection), or secondary to another infectious source. Infection can also further complicate a pre-existing access site issue such as infection of a hematoma, thrombosed pseudoaneurysm, or seroma. Skin flora from frequent dialysis cannulations result in common pathogens being Staphylococcus, Pseudomonas, or polymicrobial species. Staphylococcus and Pseudomonas are highly virulent and likely to cause anastomotic disruption. Patient Presentation and Workup Physical exam will reveal warmth, pain, swelling, erythema, induration, drainage, or pus. Occasionally, patients have nonspecific manifestations of fever or leukocytosis. Ultrasound can be used to screen for and determine the extent of graft involvement by the infection.   Treatments In AV fistulas: Localized infection can usually be managed with broad spectrum antibiotics.  If there are bleeding concerns or infection is seen near the anastomosis site, the fistula should be ligated and re-created in a clean field. In AV grafts: If infection is localized, partial graft excision is acceptable. Total graft excision is recommended if the infection is present throughout the entire graft, involves the anastomoses, occludes the access, or contains particularly virulent organisms Total graft excision may also be indicated if a patient develops recurrent bacteremia with no other infectious source identified. For graft excision, the venous end of the graft is removed and the vein is oversewn or ligated. If the arterial anastomosis is intact, a small cuff of the graft can be left behind and oversewn. If the arterial anastomosis is involved, the arterial wall must be debrided and ligation, reconstruction with autogenous patch angioplasty, or arterial bypass can be pursued. References   1. Morsy AH, Kulbaski M, Chen C, Isiklar H, Lumsden AB. Incidence and Characteristics of Patients with Hand Ischemia after a Hemodialysis Access Procedure. J Surg Res. 1998;74(1):8-10. doi:10.1006/jsre.1997.5206 2. Ballard JL, Bunt TJ, Malone JM. Major complications of angioaccess surgery. Am J Surg. 1992;164(3):229-232. doi:10.1016/S0002-9610(05)81076-1 3. Valentine RJ, Bouch CW, Scott DJ, et al. Do preoperative finger pressures predict early arterial steal in hemodialysis access patients? A prospective analysis. J Vasc Surg. 2002;36(2):351-356. doi:10.1067/mva.2002.125848 4. Malik J, Tuka V, Kasalova Z, et al. Understanding the Dialysis access Steal Syndrome. A Review of the Etiologies, Diagnosis, Prevention and Treatment Strategies. J Vasc Access. 2008;9(3):155-166. doi:10.1177/112972980800900301 5. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg. 2002;35(3):603-610. doi:10.1067/mva.2002.122025 6. Thermann F, Kornhuber M. Ischemic Monomelic Neuropathy: A Rare but Important Complication after Hemodialysis Access Placement - a Review. J Vasc Access. 2011;12(2):113-119. doi:10.5301/JVA.2011.6365 7. Dauria DM, Dyk P, Garvin P. Incidence and Management of Seroma after Arteriovenous Graft Placement. J Am Coll Surg. 2006;203(4):506-511. doi:10.1016/j.jamcollsurg.2006.06.002 8. Gargiulo NJ, Veith FJ, Scher LA, Lipsitz EC, Suggs WD, Benros RM. Experience with covered stents for the management of hemodialysis polytetrafluoroethylene graft seromas. J Vasc Surg. 2008;48(1):216-217. doi:10.1016/j.jvs.2008.01.046 9. Blumenberg RM, Gelfand ML, Dale WA. Perigraft seromas complicating arterial grafts. Surgery. 1985;97(2):194-204. 10. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4):S1-S164. doi:10.1053/j.ajkd.2019.12.001 11. Padberg FT, Calligaro KD, Sidawy AN. Complications of arteriovenous hemodialysis access: Recognition and management. J Vasc Surg. 2008;48(5):S55-S80. doi:10.1016/j.jvs.2008.08.067

I've touched on the topic of endotoxemia in past episodes of the Defiant Health podcast. In this episode, let's dive deeper into this topic that is absolutely crucial to understanding and managing SO many aspects of health, from subduing anxiety and panic, to depressive, to joint pain and skin rashes, to gastrointestinal conditions, even weight management. What is endotoxemia? Fecal microbes, so-called Gram-negative species because of the way these microbes take up stain for examination under a microscope, species such as E. coli and Salmonella, have something called lipopolysaccharide endotoxin in their cells walls. Other species, so-called Gram positive species such as Enterococcus, Staphylococcus, and Streptococcus, that stain in a different manner, have something called lipoteichoic acid in their cell walls. When these microbes die, both Gram-negative and Gram-positive, these toxic factors are released into the intestines. If these fecal microbes are confined to the colon, where they belong, a section of GI tract adapted to their presence, the entry of these toxic components are limited and current evidence is unclear in how importat this process is. The real trouble occurs, however, when fecal microbes have invaded the 24-feet of small intestine, a process we label small intetinal bacterial overgrowth, or SIBO, because the small intestine—the stomach, duodenum, jejunum, and ileum are not well-adapted to the invasion of fecal species. Here, they die, release their toxic components, which then enter the bloodstream, the process labeled endotoxemia. People with SIBO therefore have high blood levels, typically 200-400% higher, levels of endotoxin. This is how microbes in the GI Tract export their effects to all other parts of the body. So let's discuss this process and how you can take control over it to be be better able to take control over your emotions, mood, sleep, energy, weight, and numerous other aspects of health. _______________________________________________________________________________For BiotiQuest probiotics including Sugar Shift, go here.A 15% discount is available for Defiant Health podcast listeners by entering discount code UNDOC15 (case-sensitive) at checkout.*_________________________________________________________________________________Get your 15% Paleovalley discount on fermented grass-fed beef sticks, Bone Broth Collagen, low-carb snack bars and other high-quality organic foods here.* For 12% off every order of grass-fed and pasture-raised meats from Wild Pastures, go here._____________________________________________________________________________MyReuSupport the showBooks: Super Gut: The 4-Week Plan to Reprogram Your Microbiome, Restore Health, and Lose Weight Wheat Belly: Lose the Wheat, Lose the Weight and Find Your Path Back to Health; revised & expanded ed

We are back with more exciting IDWeek 2024 content. In this episode, Breakpoints hostesses Drs. Erin McCreary, Julie Ann Justo, Jeannette Bouchard, and Megan Klatt highlight more of our favorite sessions and posters at IDWeek, this episode is a must listen if you are an IDWeek nerd like us! References: Perret et al. Application of OpenAI GPT-4 for the retrospective detection of catheter-associated urinary tract infections in a fictitious and curated patient data set. 10.1017/ice.2023.189 Wiemken et al. Assisting the infection preventionist: Use of artificial intelligence for health care–associated infection surveillance. 10.1016/j.ajic.2024.02.007 Leekha et al. Evaluation of hospital-onset bacteraemia and fungaemia in the USA as a potential healthcare quality measure: a cross-sectional study. 10.1136/bmjqs-2023-016831 Diekema et al. Are Contact Precautions "Essential" for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus? 10.1093/cid/ciad571 Martin et al. Contact precautions for MRSA and VRE: where are we now? A survey of the Society for Healthcare Epidemiology of America Research Network. 10.1017/ash.2024.350 Browne et al. Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial. 10.1016/S1473-3099(24)00399-2 Protect trial: Decolonization in Nursing Homes to Prevent Infection and Hospitalization. 10.1056/NEJMoa2215254 Aldardeer et al. Early Versus Late Antipseudomonal β-Lactam Antibiotic Dose Adjustment in Critically Ill Sepsis Patients With Acute Kidney Injury: A Prospective Observational Cohort Study. 10.1093/ofid/ofae059 Schmiemann et al. Effects of a multimodal intervention in primary care to reduce second line antibiotic prescriptions for urinary tract infections in women: parallel, cluster randomised, controlled trial. 10.1136/bmj-2023-076305 Vernacchio et al. Improving Short Course Treatment of Pediatric Infections: A Randomized Quality Improvement Trial. 10.1542/peds.2023-063691 Advani et al. Bacteremia From a Presumed Urinary Source in Hospitalized Adults With Asymptomatic Bacteriuria. 10.1001/jamanetworkopen.2024.2283 Saif et al. Clinical decision support for gastrointestinal panel testing. 10.1017/ash.2024.15 Bekker et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. 10.1056/NEJMoa2407001 Montini et al. Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial. 10.1542/peds.2023-062598 Nielsen et al. Oral versus intravenous empirical antibiotics in children and adolescents with uncomplicated bone and joint infections: a nationwide, randomised, controlled, non-inferiority trial in Denmark. 10.1016/S2352-4642(24)00133-0 Kaasch et al. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial. 10.1016/S1473-3099(23)00756-9 AMIKINHAL: Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. 10.1056/NEJMoa2310307 PROPHY-VAP: Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. 10.1016/S2213-2600(23)00471-X AVENIR: Azithromycin to Reduce Mortality — An Adaptive Cluster-Randomized Trial. 10.1056/NEJMoa2312093 Thomas et al. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. 10.1093/cid/ciad458 Schuster et al. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. 10.1093/cid/ciad534 Mahadeo et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. 10.1016/S1470-2045(23)00649-6 Khoury et al. Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. 10.1016/j.ajt.2024.04.009 Spec et al. MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses—A Multicenter, Open-Label, Randomized Comparative Trial. 10.1093/ofid/ofae010

In this episode of the Micro Binfie Podcast, host Andrew Page speaks with Dr. Brooke Talbot, a recent PhD graduate from Emory University, about her research on Staphylococcus aureus, with a focus on MRSA and antibiotic resistance. Brooke shares insights into her molecular epidemiology work, discussing the complexities of tracking resistant bacterial strains in clinical settings and the significance of genomic epidemiology in public health. From honeybees to foodborne outbreaks, Brooke's diverse research background offers listeners a fascinating journey through science, microbiology, and epidemiology.

On episode #67 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 10/24 – 11/6/24. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia(Nature) Bacterial Implementation of a Pharmacist-Driven Vancomycin Area Under the Concentration-Time Curve Monitoring Program Using Bayesian Modeling in Outpatient Parenteral Antimicrobial Therapy (OFID) Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin (Nature) Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis(CID) Fungal The Last of US Season 2 (YouTube) Notes from the Field: Trichophyton mentagrophytes Genotype VII — New York City, April–July 2024 (CDC MMWR) Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients(Transplant Infectious Disease) Parasitic Outcomes of kidney transplant recipients exposed to Chagas disease under Benznidazole prophylaxis(Transplant Infectious Disease) Fake Aristotle Fakely Rails Against Fighting Inequality (Sententiae Antiquae) Need for a paradigm shift in soil-transmitted helminthiasis control (PLoS Neglected Tropical Diseases) Miscellaneous IDSA Advocacy Results in Big Win for ID in 2025 Final Medicare Rule (IDSA) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Staphylococcus Epidermidis ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

L'asticothérapie, aussi appelée thérapie par les larves ou débridement biologique, consiste à utiliser des larves de mouches stériles, principalement celles de Lucilia sericata, pour nettoyer des plaies infectées ou non cicatrisantes. Ce traitement exploite la capacité des larves à dévorer uniquement les tissus nécrotiques et infectés sans toucher les tissus sains, ce qui permet de favoriser la guérison des plaies. Voici en détail comment cela fonctionne et pourquoi cela pourrait aider à contrer la résistance aux antibiotiques. Fonctionnement de l'asticothérapie Les larves utilisées pour l'asticothérapie sont appliquées directement sur la plaie ou placées dans des petits sachets poreux pour éviter tout contact direct avec le patient. Une fois sur la plaie, elles commencent à sécréter des enzymes qui dégradent les tissus morts et infectés, les rendant plus faciles à absorber. Ensuite, les larves se nourrissent de ce tissu digéré, nettoyant efficacement la plaie de la nécrose. Au-delà de leur capacité à dévorer le tissu infecté, les larves sécrètent aussi des substances antibactériennes naturelles, comme des peptides antimicrobiens. Ces sécrétions contribuent à détruire les bactéries présentes dans la plaie, y compris celles qui résistent aux antibiotiques, comme certaines souches de *Staphylococcus aureus* résistant à la méthicilline (SARM). De plus, l'activité des larves stimule la formation de tissus de granulation et encourage la cicatrisation. Une alternative face à la résistance aux antibiotiques La résistance aux antibiotiques est une crise mondiale croissante, car de plus en plus de bactéries deviennent résistantes aux traitements conventionnels. L'asticothérapie pourrait être une solution alternative ou complémentaire, surtout pour les infections où les antibiotiques ne sont plus efficaces. Puisque les larves n'utilisent pas d'antibiotiques pour combattre les bactéries, mais plutôt des mécanismes naturels de débridement et de désinfection, elles contournent complètement le problème de la résistance. En outre, les substances antibactériennes produites par les larves sont souvent différentes des antibiotiques traditionnels. Cela signifie qu'elles peuvent s'attaquer aux bactéries d'une manière à laquelle ces dernières ne sont pas encore résistantes. Ainsi, l'asticothérapie pourrait permettre de réduire l'utilisation d'antibiotiques, en particulier dans le traitement des plaies chroniques, et ainsi diminuer la pression sélective qui conduit à la résistance. Conclusion L'asticothérapie est donc non seulement efficace pour le débridement des plaies, mais elle offre aussi un espoir dans la lutte contre les infections résistantes aux antibiotiques. En facilitant la guérison des plaies et en utilisant des substances antimicrobiennes naturelles, cette approche pourrait représenter un outil précieux pour les hôpitaux et les patients souffrant d'infections difficiles à traiter. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Pour répondre à cette question il nous faut définir ce qu'est une IST. C'est une infection sexuellement transmissible, par exemple la chlamydia, la gonorrhée, la syphilis, le VIH, l'herpès génital et le papillomavirus humain (HPV). Ces infections se propagent principalement par contact avec des fluides corporels infectés (sperme, sécrétions vaginales, sang) ou par contact direct avec des lésions ou des muqueuses infectées. De plus la majorité des IST sont causées par des virus, des bactéries ou des parasites qui ne vivent que brièvement à l'extérieur du corps humain. Par exemple, le VIH ne survit pas longtemps à l'air libre et se dégrade rapidement à l'extérieur d'un environnement corporel. D'autres agents, comme les bactéries de la chlamydia ou de la gonorrhée, sont également sensibles aux conditions extérieures. Quant au virus de l'herpès, bien qu'il soit relativement résistant, il nécessite un contact direct avec des muqueuses infectées pour se transmettre. Donc la surface des toilettes ne fournit pas un environnement viable pour ces agents, car ils ont besoin d'humidité et de chaleur corporelle pour se multiplier et survivre. Vous le comprenmez, les IST ne sont pas un risque majeur dans les toilettes publiques. Cependant, attention, d'autres types d'infections peuvent théoriquement être contractées via des surfaces contaminées, comme les infections urinaires, les infections cutanées par *Staphylococcus aureus* (y compris le staphylocoque doré), ou des infections par des champignons (mycoses). Mais disons le ces risques restent faibles. Le contact direct prolongé et l'existence de micro-coupures dans la peau peuvent légèrement augmenter la probabilité de transmission de ces infections, mais l'hygiène personnelle, comme se laver les mains après utilisation et éviter de toucher directement des surfaces, réduit le risque de transmission. ConclusionEn résumé, les toilettes publiques ne constituent pas un risque pour la transmission des IST, car celles-ci se propagent via des contacts sexuels intimes et nécessitent des conditions spécifiques pour survivre. Pour rester en bonne santé dans les toilettes publiques, il est suffisant de prendre des mesures d'hygiène simples, telles que l'utilisation de protections en papier pour les sièges, se laver les mains avec du savon, et éviter tout contact direct prolongé avec les surfaces. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Drs. Cesar Arias (@SuperBugDoc) and Katie Barber join Dr. Julie Ann Justo (@julie_justo) to discuss what is hot-off-the-presses for gram-positive bacterial infections and it's a total party vibe! They review the latest news for recent and ongoing clinical trials (DOTS, DISRUPT, and SNAP trials), discuss hope for novel clinical tests of the cefazolin inoculum effect in staphylococci, and explore the fascinating changes in virulence and potential therapeutic options for the most challenging enterococci. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Climate Change and Antimicrobial Resistance. Editors in Conversation Podcast. American Society for Microbiology. Oct 2023. Is More Better? The Role of Combination Therapy for MRSA. Breakpoints Podcast Episode #30. Society of Infectious Diseases Pharmacists. Turner NA, et al. DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia. ESCMID Global 2024. April 2024. NCT04775953. Real-world dalbavancin observational cohort: Rebold N, et al. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. PMID: 38427289. Exebacase DISRUPT trial : Fowler VG Jr, et al. Clin Infect Dis. 2024 Jun 14;78(6):1473-1481. doi: 10.1093/cid/ciae043. PMID: 38297916. @snap_trial tweet of Breaking News. Aug 2024. Investigator Resources for the SNAP trial. Sept 2024: https://www.snaptrial.com.au/for-investigators#interim Cefazolin inoculum effect on mortality in MSSA bacteremia : Miller WR, et al. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123. PMID: 29977970. Prevalence of cefazolin inoculum effect in MSSA and modified rapid nitrocefin test for detection: Carvajal LP, et al. Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898-24. PMID: 39345182. LiaX as surrogate for cell envelope stress in Enterococus faecium: Axell-House DB, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. PMID: 38289081. Shorter is better for uncomplicated streptococcal bacteremia: Clutter DS, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022024. doi: 10.1128/aac.00220-24. PMID: 38975753. Short vs. long antibiotic duration in Streptococcus pneumoniae bacteremia: Crotty M, et al. Open Forum Infect Dis. 2024 Aug 30;11(9):ofae478. doi: 10.1093/ofid/ofae478. PMID: 39257675. This podcast is powered by Pinecast.

In this episode, I'm getting real about my gut health journey after some eye-opening results from my GI MAP stool test. We'll chat about Candida overgrowth, why it's been a total game-changer for my health, and what I'm doing to get things back on track. If you've been dealing with bloating, fatigue, or just feeling off, this episode is for you! Key Topics: MY GI MAP stool test results and who Im working with Why Does Candida Overgrow? My Symptoms: I've been dealing with a range of issues, from bloating and fatigue to skin problems and brain fog. It's been a wild Gut Dysbiosis: I found out I have low good bacteria and high Staphylococcus levels, which means my digestion isn't great. Low digestive enzymes are making it hard to absorb nutrients, leaving me feeling bloated and sluggish. Healing Protocols: I go into my healing protocols that were given to be by my functional dietician. NAKED Fitness Challenge Fitness + Wellness Coaching Apply for Private Mentorship Connect with me on Instagram

We use it to chase away flu and vampires. It gives us an odor which makes kissing impossible, but we still add it to our food to spice it up. Yes, we are talking about garlic. This stinking rose is full of cloves, contradictions, and mysteries. We've put together some amazing facts about garlic we are sure you did not know. And, wait for the best part, we are going to tell you what will happen to you if you put garlic under your pillow. TIMESTAMPS Garlic is good for your skin 0:48 It can help you keep your hair thick 1:40 Garlic can repel mosquitoes 2:36 It will take your splinters away 3:19 Garlic can prevent food poisoning 3:59 Garlic is good for your heart 4:31 Why should you ever put garlic under your pillow? 5:06 Garlick Milk Drink 6:18 SUMMARY Garlic is very rich in antioxidants, which are important for our good health and can work miracles. Miracles, like fighting acne. Apparently, the antioxidants garlic contains can kill the acne bacteria. Try making some hair masks mixing garlic juice and coconut or castor oil and honey. The easiest way to do is to add olive oil to garlic, one tablespoon per clove, and let it stir for one or two weeks in the refrigerator before you rub it into your hair. It is also a good idea to use it on your scalp. If you run out of your usual repellent or if you want to try something new and natural, we have a secret tip for you. Some scientists in India found out that mosquitoes, much like vampires, hate garlic. You can try applying garlic directly to your skin, or keep it by your side, and you will love the result. All you care about is removing them. It turns out garlic can be of help in this situation! For many years, it was used as a remedy for splinters. All you have to do is put a slice of garlic on your splinter, attach it with bandage or tape and wait for the result. Research has shown that fresh garlic can help to prevent food poisoning! It kills bacteria like E. coli, Staphylococcus aureus, and Salmonella enteritidis. According to one study, in some cases, garlic can do even better than some antibiotics. Eating enough garlic every day will help to lower the amount of cholesterol in your body. Garlic is rich in Allicin, which is good at performing this task thanks to its antioxidant properties. It is also of great help in keeping the optimal blood pressure and blood sugar levels.  Over the centuries, garlic has proved to be a great help to those who find it difficult to fall asleep. How, you might ask? Well, here is an explanation. Garlic contains sulfur, which gives a rather strong odor we all know about it. While this odor seems too repellent at first, you get used to it after a few days, and its calming effect will help you sleep as sound as a baby! More than that, it will recharge you for the next day and help you increase your productivity. Subscribe to Bright Side : https://goo.gl/rQTJZz ---------------------------------------------------------------------------------------- Our Social Media: Facebook:   / brightside   Instagram:   / brightgram   5-Minute Crafts Youtube: https://www.goo.gl/8JVmuC  ---------------------------------------------------------------------------------------- For more videos and articles visit: http://www.brightside.me/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Don and Professor Ben talk about the risks from eating a properly cooked egg with a crack in it. Dr. Don - not risky

Dr. Don and Professor Ben talk about the risks drinking beer from glasses when the bottle has been inside the glass and in contact with the beer. Dr. Don - not risky

Interview with Maria Teresa García-Romero, MD, MPH, author of Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Hosted by Adewole S. Adamson, MD. Related Content: Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis

Interview with Maria Teresa García-Romero, MD, MPH, author of Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Hosted by Adewole S. Adamson, MD. Related Content: Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis

Joya Griffin, DVM, DACVD, is an Ohio native and graduated from Cornell University College of Veterinary Medicine in 2006. While attending Cornell, she earned numerous awards, including the Dermatology Service Award for her aptitude in clinical dermatology and her research on Malassezia otitis externa. After graduation, she completed an internship at the VCA Berwyn and Aurora animal hospitals in the Chicago area, where she was awarded the Intern Abstract Award for her presentation on methicillin-resistant Staphylococcus aureus. Griffin returned to Cornell in 2007 for a residency in dermatology and, after completing her residency training program, served 1 year as an instructor of dermatology, teaching fourth-year clinical students and lecturing to underclassmen on bacterial, fungal, and immune-mediated skin diseases. Griffin became a diplomate of the American College of Veterinary Dermatology in August 2010 and joined the Animal Dermatology Group. She has a special interest in fungal and immune-mediated skin diseases, as well as feline and equine dermatology. She enjoys lecturing to fellow veterinarians, mentoring residents, and teaching the veterinary students who extern with her. Griffin also stars in the Nat Geo WILD television series Pop Goes the Vet With Dr Joya, which highlights the challenging and mysterious cases she encounters in veterinary dermatology. Griffin always strives to care for her patients as if they are her own pets and loves building a long-lasting relationship with their pet parents. Outside of work, Griffin enjoys spending time with her family and pets. She is married to Forrest Cummings, DVM, DACVIM (SAIM), a veterinary internal medicine specialist, and they have 3 children: Caden and boy/girl twins Coby and Carter. They have a kitten named Donut and 2 dogs, Guri and Magic. Griffin loves traveling, eating the delicious meals her hubby cooks for her, and working out. 

Rosemary Bartel had no idea her life was going to take a turn when she went to a hospital near her home in Chilton, Wisconsin in the United States for standard knee replacement surgery – her second such operation. She was ready to work hard to recover and return to her busy job at her Roman Catholic diocese. But Rosie developed an all-too-common infection known as MRSA—methicillin-resistant Staphylococcus aureus. It's one of the best-known examples of antimicrobial-resistant microbes, often called superbugs. The United Nations is devoting a high-level meeting to the problem in September 2024 in the hopes of getting nations to do more to fight antimicrobial resistance or AMR.Now, 15 years later, Rosie has had her leg and hip amputated because the infection got into her bones. She has suffered numerous other infections, been in comas, lost her job, lost her health insurance, and lost most of the life she had loved.“I will probably be paying hospital bills for the rest of my life,” Rosie tells One World, One Health. Rosie is one of the luckier victims of AMR. She's still alive. Five million people a year die from complications caused by these drug-resistant germs. Now, Rosie shares her story as widely as she can as part of the Patient Family Partners Network, a group of patient advocates working to improve healthcare in the United States, and the Leapfrog Group, a nonprofit patient safety advocacy organization. She's also written a book, “Rosie's Story,” about her experience with this devastating and unending infection. Listen as Rosie describes what happened to her and what she hopes to do to help stop it from happening to others

Drs. Jim Rhodes and Molly Steed join host Jeannette Bouchard to discuss all things related to optimal dosing of daptomycin. This podcast episode provides insight on why dosing matters with this antibiotic, especially with certain organisms (looking at you, E. faecium), why weight matters with dosing, and what that pesky CPK means. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/  References: Fixed-dose daptomycin in Staphylococcus aureus: doi 10.1002/phar.4602 High dose daptomycin for VRE: doi 10.1093/cid/ciw815 This podcast is powered by Pinecast.

On episode #61 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 8/1/20 - 8/14/24.  Host: Daniel Griffin and Sara Dong  Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral nPEP quick guide (AIDS Education & Training Center Program) Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide PREP after sexual assault (OFID) Adopting Early Testing for Perinatal Hepatitis C (Journal of Pediatric Infectious Diseases Society) Bacterial Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis (OFID) Trimethoprim-Sulfamethoxazole for Staphylococcus Aureus Bacteremia Prophylaxis in Patients on Hemodialysis (OFID) Human monocytotropic ehrlichiosis(PLoS Neglected Tropical Diseases) Human granulocytotropic anaplasmosis (PLoS Neglected Tropical Diseases) Bifidobacterium and Lactobacillus Probiotics for Preterm Infants (JAMA Network: JAMA Pediatrics) Rapid Implementation of Blood Culture Stewardship (CID) BD BACTEC Blood Culture Bottle Shortage - (IDSA) Fungal The Last of US Season 2 (YouTube) Clinical characteristics and mortality risks among critically ill patients with culture-proven coccidioidomycosis(OFID) Poor Clinical and Microbiologic Outcomes in C. auris Bloodstream Infection (CID) Parasitic Soap is lethal for Schistosoma mansoni cercariae (PLoS Neglected Tropical Diseases) Treatment of uncomplicated hepatic cystic echinococcosis (Cochrane Library) Blood exposure to Babesia microti(Cambridge Core) Miscellaneous Absence of Cerebrospinal Fluid Pleocytosis in Encephalitis (CID) Encephalitis due to Infection with Normocellular Cerebrospinal Fluid (CID) Podoconiosis and mental health (PLoS Neglected Tropical Diseases) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In this episode of the ICHE Podcast, we delve into the topic of Staphylococcus aureus (S. aureus) and Methicillin-resistant Staphylococcus aureus (MRSA), focusing on healthcare-associated infections and transmission. Our expert panel of authors from recently published ICHE papers includes Anthony Harris, MD, MPH, Elise Martin, MD, MS, and Philip M. Polgreen, MD, MPH. Listen as they discuss the prevalence of these infections, the risks they pose, and the strategies that can be employed to reduce transmission in both healthcare settings and households. At the conclusion of today's episode, each participant offers a practical, actionable recommendation for listeners.

Is getting rid of Staph aureus in the gut the key to improving eczema? And can we control it without antibiotics? Join us as we ask these questions and more of Dr. Michael Otto, Chief of the Pathogen Molecular Genetics Section at the National Institute of Allergies and Infectious Diseases. (And if you like our podcast, consider supporting it with a tax deductible donation). Research mentionedProbiotic for pathogen-specific Staphylococcus aureus decolonisation in Thailand: a phase 2, double-blind, randomised, placebo-controlled trialCommensal Staphylococcus epidermidis contributes to skin barrier homeostasis by generating protective ceramides The association between Staphylococcus aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohortSkin microbiota analysis-inspired development of novel anti-infectivesCombined antibiotic, steroid, and moisturizer for atopic dermatitis: A two‐year case series of patient‐reported outcomes

Dr. Don and Professor Ben talk about the risks from vacuum packaged cheddar cheese stored for 24 hours at room temperature. Dr. Don - not risky

This StAR episode features the CID State-of-the-Art Review on Staphylococcus aureus bacteremia - controversies in clinical practice.Our guest stars this episode are: Daniel Minter (UCSF)Sarah Doernberg (UCSF)Journal article link: Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. Clin Infect Dis. 2023 Nov 30;77(11):e57-e68. doi: 10.1093/cid/ciad500. PMID: 37950887.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/11/1489/7453594From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

On episode #58 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 6/20 – 7/3/24. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Drink more coffee, reduces risk for SARS-C0V-2 infection (Cell & Bioscience) Cannabis, tobacco…smoking in general NOT good for preventing COVID-19 (JAMA Network OPEN) EBV and KSHV caused HIV associated cancers and lymphoproliferative disorders (Clinical Microbiology Reviews) Where in the CNS can dolutegravir, tenofovir, lamivudine and efavirenz be found? (JID) Therapeutic management of Varicella-Zoster virus meningitis (OFID) Bacterial Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections (LANCET Infectious Diseases) IDSA guidelines (Columbia University) Guideline-Concordant Therapy for community-acquired pneumonia in the Hospitalized Population (OFID) Interpretive Criteria piperacillin/tazobactam susceptibility test for Enterobacterales (CID) FDA approval forCAPVAXIVE (FDA) 21 valent pneumococcal vaccine approved (Nature Reviews drug discovery) Antimicrobial resistant Staphylococcus aureus isolates (JAMA Network Open) Broad-spectrum antibiotic use for suspected community-onset sepsis (JAMA Network Open) Fungal The Last of Us ( Wikipedia) Challenges to vaccinating against coccidioidomycosis (OFID) Cryptococcosis: the story (OFID) Pneumocystis pneumonia: clinical spectrum, prophylaxis and delayed treatment (Intensive Care Medicine) Improve utilization of 1,3 β-D-glucan Testing(OFID) Music is by Ronald Jenkees

Have you tried using topical zinc for eczema, psoriasis, or other rashes yet? Because spoiler: when you use the correct form of zinc topically, it can be a game changer for your skin rash. Why? So many skin rash warriors are deficient in this crucial mineral. And taking zinc orally just doesn't always cut it for most people, unfortunately.So if you haven't yet explored the skin rash-zinc connection, let's take a look at why topical zinc can be so helpful, things you need to watch out for when using it, and what to look for in a topical zinc formula — because not all zinc is created the same.Before we dive in: Are you tired of chasing skin rash remedies that seem to work for everyone else but you? Do you find something that seems to help…only to have your fleeting victory erased by a massive flare? This happens because everyone's root cause of their rash is different — and most people have several root causes going on at once. So when you get one fire under control, another pops up. It's exhausting.Here's the exact process I take my private clients through to help them heal: my FREE Skin Rash Root Cause Finder. A quick and easy-to-use workbook that will help you narrow down the underlying causes of your rash so you can get to work stopping it! Download it here and let's figure this out, together! In This Episode:What are the topical zinc benefits for skin rashes?If you have a skin rash, does that mean you have a zinc deficiency?Is zinc good for eczema?Should you use nano or non-nano zinc oxide?Drawbacks of topical zinc and why you might not want to use itReal zinc and eczema resultsQuotes“There was also a statistically significant decrease in the occurrence of Staphylococcus aureus in the wounds of study participants, suggesting zinc could have anti-microbial properties.”“Generally, we often see a relationship between lower levels of zinc in the body and eczema (and other skin complications like hidradenitis suppurativa, acne, rosacea, seborrheic dermatitis, psoriasis, vitiligo, and melasma)”LinksHealthy Skin Show ep. 169: Why Is Zinc So Important For Your Skin?Healthy Skin Show ep. 172: Why Use Zinc Cream For Skin RashesDermaQuell Z+ Rebuilder – https://www.quellshop.com/products/z-rebuilderALSO – we offer all three full 2oz jars in the Ultimate Quell kit – https://www.quellshop.com/products/ultimate-quell-kitUse coupon code QUELL10 to get $10 off your first orderOR try the Quell skincare sample pack that includes Z+ Rebuilder along with Daily Butter and Nourish Butter creams for only $12.95 (free shipping) - https://www.quellshop.com/products/dermaquell-skincare-sample-kit (especially great for those who are nervous to purchase a full product without trying it first. Each sample is a sealed 0.26oz sachet packet and includes a $12.95 store credit to use on anything in the shop). 

Apple cider vinegar is revered in wellness spaces for its health-giving benefits, but is there anything to it?There are claims it can aid with weight loss, boost your gut microbiome and manage blood sugar levels. Norman and Tegan explain how this salad dressing became so famous, and what the science tells us.References:Apple cider vinegar for weight management in Lebanese adolescents and young adults with overweight and obesity: a randomised, double-blind, placebo-controlled study Antibacterial apple cider vinegar eradicates methicillin resistant Staphylococcus aureus and resistant Escherichia coliThe improvement effect of apple cider vinegar as a functional food on anthropometric indices, blood glucose and lipid profile in diabetic patients: a randomized controlled clinical trialGot a health question? Shoot us a line @ABCHealth on Instagram, or send a voice memo to thatrash@abc.net.au. We'd love to hear from you!

Episode Notes The Society of Infectious Diseases Pharmacists is excited to invite you to the first ever meeting (via Breakpoints) of The Tortured Stewards & Surgeons Department. Today's agenda items: optimal management of perioperative antibiotics and prevention of surgical site infections. Drs. Trisha Peel (@DrTrishaPeel), Michael Calderwood (@CalderwoodMD) and Patch Dellinger join Dr. Jillian Hayes (@thejillianhayes) to discuss some of the controversies we encounter while managing antibiotics in the perioperative space. Does anyone really need post-op antimicrobial prophylaxis longer than 24 hours? Where should vancomycin be fitting into surgical prophylaxis regimens? Can we truly give pre-operative cefazolin to patients with a penicillin allergy? Tune in for the answers to these questions and more! Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp If you'd like more information about the CALIPSO trial, please visit this link: https://www.anzca.edu.au/profiles/ctn-trials/underway/calipso Bibliography SSI Infection Prevention Review: https://jamanetwork.com/journals/jama/article-abstract/2800424#:~:text=Six%20are%20supported%20by%20randomized,use%20a%20chlorhexidine%20gluconate%2Dalcoho Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update: https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9D American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update: https://journals.lww.com/journalacs/citation/2017/01000/american_college_of_surgeons_and_surgical.8.aspx  2017 CDC Guidelines: https://jamanetwork.com/journals/jamasurgery/fullarticle/2623725  2018 WHO Guidelines: https://arthroplasty.biomedcentral.com/articles/10.1186/s42836-022-00113-y  ASHP Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery: https://www.ashp.org/surgical-guidelines  Surgeons as Stewards: https://journals.lww.com/journalacs/citation/2020/12000/perioperative_antibiotic_prophylaxis__surgeons_as.23.aspx  Li et al, Arthroplasty 2022: https://arthroplasty.biomedcentral.com/articles/10.1186/s42836-022-00113-y  Dutch Arthroplasty Register Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023957/  de Jonge Meta-Analysis on duration and incidence of SSI: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30084-0/abstract  Prolonged Antibiotic Prophylaxis After Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance: https://www.ahajournals.org/doi/10.1161/01.cir.101.25.2916?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed RCT - Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: https://jamanetwork.com/journals/jama/article-abstract/2810510  NYU Langone Study - Preventing Surgical Site Infections: A Randomized, Open-Label Trial of Nasal Mupirocin Ointment and Nasal Povidone-Iodine Solution: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=91dee3e1445adb80d533f2c210816a3285254e3a  Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty: https://www.nejm.org/doi/full/10.1056/NEJMoa2301401 What Is the Primary Driver of Preoperative Vancomycin Use? It's Not Methicillin-resistant Staphylococcus aureus—or Allergy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744972/  Drug allergy: a 2022 practice parameter update: https://www.jacionline.org/article/S0091-6749(22)01186-1/fulltext  Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy: https://www.surgjournal.com/article/S0039-6060(18)30307-6/abstract#%20  Timing of Surgical Prophylaxis RCT: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30176-7/abstract  Propensity Score-Weighted Analysis of Postoperative Infection in Patients With and Without Preoperative Urine Culture: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2815528

HEALTH NEWS   An apple cider vinegar drink a day? New study shows it might help weight loss Food Additive in Pizza, Pancakes Linked to Lower Sperm Counts Ramadan fasting may protect patients with heart problems, say researchers An investigation into the potential association between nutrition and Alzheimer's disease Breakthrough Discovery Shows That Resonant Frequencies Can Kill Cancer Cells Study finds interactions with dogs can increase brainwaves associated with stress relief and heightened concentration     An apple cider vinegar drink a day? New study shows it might help weight loss Holy Spirit University of Kaslik (Lebanon), March 13, 2024   An experimental study, released today, looks into whether apple cider vinegar could be effective for weight loss, reduce blood glucose levels and reduce blood lipids (cholesterol and triglycerides). A double-blinded, randomized, clinical trial in a group of overweight and obese young people aged from 12–25 years suggest it could reduce all three—but it might not be as simple as downing an apple cider vinegar drink a day. The participants were instructed to consume either 5, 10 or 15ml of apple cider vinegar diluted into 250ml of water each morning before they ate anything for 12 weeks. A control group consumed an inactive drink (a placebo) made (from lactic acid added to water) to look and taste the same. After a period of three months apple cider vinegar consumption was linked with significant falls in body weight and body mass index (BMI). On average, those who drank apple cider vinegar during that period lost 6–8kg in weight and reduced their BMI by 2.7–3 points, depending on the dose. They also showed significant decreases in the waist and hip circumference. The authors also report significant decreases in levels of blood glucose, triglycerides, and cholesterol in the apple cider groups. While the study appears promising, there are also reasons for caution. The study participants were aged from 12 to 25, so we can't say whether the results could apply to everyone.   Food Additive in Pizza, Pancakes Linked to Lower Sperm Counts University of Kentucky, March 11, 2024 An ingredient commonly found in many baked goods and processed foods — including school lunches — may cause oxidative stress, DNA damage and decreased testosterone levels and sperm counts in male mammals. Sodium aluminum phosphate is an additive used in food products as an emulsifying agent, leavening acid and stabilizer. It is a white, odorless solid slightly soluble in water. The widespread use of sodium aluminum phosphate in everyday food products and commercially baked goods such as cakes, muffins and biscuits, and self-rising flours and baking powders. It is also used in processed cheeses to improve texture and melting properties. A peer-reviewed scientific literature on aluminum reproductive toxicity by Robert A. Yokel, Ph.D., published in Critical Reviews in Toxicology found aluminum exposure can lead to adverse reproductive outcomes in male and female mammals. Yokel's analysis revealed that “male reproductive endpoints were significantly affected after exposure to lower levels of Al [aluminum] than females.” In both male and female mice and rats, increased aluminum intake resulted in higher concentrations of the metal in the fetus, placenta and testes.   Ramadan fasting may protect patients with heart problems, say researchers University of Sharjah (United Arab Emirates) & University of Utah, March 13, 2024 Those observing Ramadan may have their cholesterol, other lipids, and inflammatory markers in their blood reduced. This is the conclusion of a group of scientists examining the model of Ramadan Intermittent Fasting (RIF) in overweight and obese people. "RIF is associated with improvements in plasma sphingosine, sphinganine sphingomyelin, and dihydrosphingomyelin lipid species," the scientists write in their study published in Scientific Reports. RIF is a special type of intermittent fasting during which fasting Muslims refrain from eating, drinking (including water), smoking, or engaging in sexual activities from pre-dawn to sunset. The fasting duration differs depending on geographical location, but it is generally estimated to last between 12-17 hours a day. The daily average fasting duration for Muslims worldwide is reported to be approximately 15 hours per day, depending on location.   An investigation into the potential association between nutrition and Alzheimer's disease Capital Medical University (China) (Frontiers) Malnutrition is the most common nutritional issue in Alzheimer's disease (AD) patients, but there is still a lack of a comprehensive evaluation of the nutritional status in AD patients. This study aimed to determine the potential association of various nutritional indices with AD at different stages. Lower levels of total protein, albumin, globulin, and apolipoprotein A1 were associated with AD (all p 

Ever wonder why some people who get exposed to colds or the flu get really ill while others experience mild symptoms or don't get sick at all? Fortunately, today's guest is here to provide answers to this mystery. An authority on the microbiome, Dr. Robynne Chutkan, is here to tell us all about the remarkable flora residing in our intestines and how feeding it the right foods can promote health, prevent disease, and even help us with our weight. Dr. Chutkan is a board-certified gastroenterologist at Georgetown Hospital, founder of the Digestive Center for Wellness, and author of the books Gutbliss, The Microbiome Solution, The Bloat Cure, and her most recent book, The Anti-Viral Gut, where she tackles the complexities of intestinal bacteria and how it relates to our immune system. She's been a featured expert on several media outlets, including The Today Show and CBS This Morning.    If you're a person interested in strengthening your immune system, or you've experienced digestive troubles, or you're just human, then this episode is definitely for you!   “For a vaginal birth, as the baby's head crowns, it turns posteriorly to face the tush, and it does that to swallow a mouthful of microbes because that area between the vaginal opening and the anus, that area we call the perineum, is full of microbes. It is one of the most microbially rich parts of the body. So, as the baby is coming out, it swallows a mouthful of the mother's microbes, and those important microbes become the founding species for the baby's microbiome. Babies that are born vaginally have that benefit. Babies that are born via C-section don't get that opportunity, and as a result, they're colonized with hospital-acquired Staphylococcus aureus.” - Dr. Robynne Chutkan   What we discuss in this episode: - What the microbiome is and how it relates to overall human health - Viruses and human DNA - The microbiome and immunity - Important tips for expecting mothers - Causes of intestinal permeability - The benefits of being in nature on the microbiome  - Tips to improve your microbiome  - The effects of stress on the gut and immunity   Resources: - Website: Dr. Robynne Chutkan - https://robynnechutkan.com/ - Books: Books by Robynne Chutkan - https://robynnechutkan.com/books/ - Instagram: https://www.instagram.com/gutbliss/?hl=en - BiOptimizers Magnesium Breakthrough: bioptimizers.com/switch4good - http://bioptimizers.com/switch4good - Vote for the Switch4Good podcast here: https://bit.ly/s4gpodcast   ★☆★ Click the link below to support the ADD SOY Act! ★☆★ https://switch4good.org/add-soy-act/ ★☆★ Share the website and get your resources here ★☆★ https://kidsandmilk.org/ ★☆★ Send us a voice message and ask a question. We want to hear from you! ★☆★ https://switch4good.org/podcast/ ★☆★ Dairy-Free Swaps Guide: Easy Anti-Inflammatory Meals, Recipes, and Tips ★☆★ https://switch4good.org/dairy-free-swaps-guide ★☆★SUPPORT SWITCH4GOOD★☆★ https://switch4good.org/support-us/ ★☆★ JOIN OUR PRIVATE FACEBOOK GROUP ★☆★  https://www.facebook.com/groups/podcastchat ★☆★ SWITCH4GOOD WEBSITE ★☆★ https://switch4good.org/ ★☆★ ONLINE STORE ★☆★ https://shop.switch4good.org/shop/ ★☆★ FOLLOW US ON INSTAGRAM ★☆★ https://www.instagram.com/Switch4Good/ ★☆★ LIKE US ON FACEBOOK ★☆★ https://www.facebook.com/Switch4Good/ ★☆★ FOLLOW US ON TWITTER ★☆★ https://twitter.com/Switch4GoodOrg ★☆★ AMAZON STORE ★☆★ https://www.amazon.com/shop/switch4good ★☆★ DOWNLOAD THE ABILLION APP ★☆★ https://app.abillion.com/users/switch4good

Erin is flying solo this episode and welcomes her dear friend Stevie Nelson to the weight room. These two talk learning comedy in the pool, having MRSA (Methicillin-resistant Staphylococcus aureus) and why swimming is a great workout. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.